C-A3TNHemostemix
autologous stem cells, angiogenic cell precursors, ischemia
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-A3TN
C-A3TNC-A3TNautologous stem cells, angiogenic cell precursors, ischemia
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Hemostemix autologous stem cells, angiogenic cell precursors, ischemia
Hemostemix is evaluating ACP-01, an investigational autologous stem cell therapy derived from a patient's own blood. The company studies ACP-01 for ischemic conditions including peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, vascular dementia, and wound-related ischemic disease. Its proprietary cell processing platform is described as supporting reproducibility, quality control, and consistent preparation of ACP-01 in regulated research environments.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Hemostemix — Translational · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic